Quick Answer
Anebulo Pharmaceuticals, Inc. reported Stockholders Equity of $11.66 million for the year ending 2025.
- Anebulo Pharmaceuticals, Inc. showed an increase of +205.8% in Stockholders Equity from 2024 to 2025.
- This data is from Anebulo Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$411.1 thousand | Q4 2020: -$719.0 thousand | Q1 2021: -$9.44 million | Q3 2021: $19.89 million | Q4 2021: $18.91 million | Q1 2022: $17.16 million | Q3 2022: $19.12 million | Q4 2022: $15.52 million | Q1 2023: $12.94 million | Q3 2023: $8.33 million | Q4 2023: $6.49 million | Q1 2024: $4.99 million | Q2 2024: $3.81 million | Q3 2024: $1.90 million | Q4 2024: $14.96 million | Q1 2025: $13.46 million | Q2 2025: $11.66 million | Q3 2025: $9.74 million | Q4 2025: $7.94 million.
- Over the full 6 years of available data (2020 to 2025), Anebulo Pharmaceuticals, Inc.'s Stockholders Equity has grown by 6,912.0%.
- Historical annual values: Fiscal year 2025: $11.66 million | Fiscal year 2024: $3.81 million | Fiscal year 2023: $10.60 million | Fiscal year 2022: $15.07 million | Fiscal year 2021: $21.41 million | Fiscal year 2020: -$171.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: